Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06388161Recruiting

Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology

Role: lead

NCT06173076Recruiting

A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis

Role: lead

NCT06388174Recruiting

Idiopathic Generalized Epilepsy Syndromes

Role: lead

All 3 trials loaded